References
- Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722–727.
- Lake F, Proudman S. Rheumatoid arthritis and lung disease: from mechanisms to a practical approach. Semin Respir Crit Care Med. 2014;35:222–238.
- Puéchal X, Génin E, Bienvenu T, et al. Poor survival in rheumatoid arthritis associated with bronchiectasis: a family-based cohort study. PLoS One. 2014;9:e110066.
- Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
- Boyton RJ, Reynolds CJ, Quigley KJ, et al. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin Exp Immunol. 2013;171:117–123.
- Tamiko T, Chiaki H, Koji O, Tomohisa B, Takashi O. Pathologic features of myeloperoxidase anti-nuetrophil cytoplasmic antibody positive interstitial pneumonia in comparison with idiopathic pulmonary fibrosis: new insight into the cystic lesions. Rheumatology (Oxford). 2017;56(Suppl 3):iii8.
- Ryu JH, Myers JL, Swensen SJ. Bronchiolar disorders. Am J Respir Crit Care Med. 2003;168:1277–1292.
- Williams T, Eidus L, Thomas P. Fibrosing alveolitis, bronchiolitis obliterans, and sulfasalazine therapy. Chest. 1982;81:766–768.
- Boddana P, Webb LH, Unsworth J, et al. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil-treated renal transplant recipients: an emerging clinical phenomenon?. Clin Transplant. 2011;25:417–419.
- Pijnenburg MW, Cransberg K, Wolff E, et al. Bronchiectasis in children after renal or liver transplantation: a report of five cases. Pediatr Transplant. 2004;8:71–74.
- Anaya JM, Diethelm L, Ortiz LA, et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:242–254.
- Geri G, Dadoun S, Bui T, et al. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis. 2011;11:304.
- Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106:1591–1599.
- Reynisdottir G, Karimi R, Joshua V, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66:31–39.